Graham Capital Management L.P. Makes New $766,000 Investment in Amphastar Pharmaceuticals, Inc. $AMPH

Key Points

• Graham Capital Management L.P. has invested approximately $766,000 in Amphastar Pharmaceuticals, Inc., acquiring 26,424 shares during the first quarter.
• The stock has seen recent adjustments from various analysts, with Piper Sandler lowering its target price from $30 to $25, and Needham & Company LLC upgrading it to a "buy" with a price target of $36.
• As of the latest filing, institutional investors own 65.09% of Amphastar Pharmaceuticals' stock, indicating strong institutional interest in the company.

Graham Capital Management L.P. bought a new position in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 26,424 shares of the company's stock, valued at approximately $766,000. Graham Capital Management L.P. owned approximately 0.06% of Amphastar Pharmaceuticals as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. TD Asset Management Inc boosted its stake in Amphastar Pharmaceuticals by 20.2% during the first quarter. TD Asset Management Inc now owns 2,212,142 shares of the company's stock worth $64,130,000 after acquiring an additional 371,856 shares in the last quarter. Systematic Financial Management LP bought a new stake in Amphastar Pharmaceuticals in the fourth quarter valued at $9,147,000. Royce & Associates LP increased its stake in Amphastar Pharmaceuticals by 2,684.3% in the first quarter. Royce & Associates LP now owns 247,858 shares of the company's stock valued at $7,185,000 after purchasing an additional 238,956 shares in the last quarter. Boston Trust Walden Corp raised its holdings in shares of Amphastar Pharmaceuticals by 24.2% during the first quarter. Boston Trust Walden Corp now owns 1,215,624 shares of the company's stock valued at $35,241,000 after purchasing an additional 236,704 shares during the period. Finally, Epoch Investment Partners Inc. boosted its position in shares of Amphastar Pharmaceuticals by 14.5% during the 1st quarter. Epoch Investment Partners Inc. now owns 1,261,307 shares of the company's stock worth $36,565,000 after purchasing an additional 160,034 shares in the last quarter. 65.09% of the stock is currently owned by institutional investors.

Amphastar Pharmaceuticals Stock Up 0.8%

NASDAQ AMPH traded up $0.23 during trading hours on Friday, hitting $29.42. The company's stock had a trading volume of 414,943 shares, compared to its average volume of 609,510. The company has a market capitalization of $1.37 billion, a PE ratio of 11.02 and a beta of 0.80. The company has a current ratio of 3.29, a quick ratio of 2.21 and a debt-to-equity ratio of 0.80. Amphastar Pharmaceuticals, Inc. has a 52 week low of $20.39 and a 52 week high of $53.96. The company's 50-day simple moving average is $25.21 and its two-hundred day simple moving average is $25.67.

Analyst Upgrades and Downgrades

Several analysts have recently commented on AMPH shares. Piper Sandler reduced their target price on Amphastar Pharmaceuticals from $30.00 to $25.00 and set a "neutral" rating for the company in a research note on Friday, August 8th. JPMorgan Chase & Co. reiterated a "neutral" rating and issued a $30.00 price target (down previously from $45.00) on shares of Amphastar Pharmaceuticals in a report on Monday, May 12th. Needham & Company LLC raised Amphastar Pharmaceuticals from a "hold" rating to a "buy" rating and set a $36.00 price objective for the company in a research note on Tuesday, August 12th. Finally, Bank of America upped their target price on Amphastar Pharmaceuticals from $28.00 to $32.00 and gave the stock a "neutral" rating in a research report on Tuesday, August 26th. Two investment analysts have rated the stock with a Buy rating and three have assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Amphastar Pharmaceuticals has an average rating of "Hold" and an average target price of $31.60.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.